Somatostatin receptor expression in Hurthle cell cancer of the thyroid

Seza A. Gulec, Aldo N. Serafini, Kasi S. Sridhar, Kamil R. Peker, Anurag Gupta, W. Jarrard Goodwin, George N. Sfakianakis, Frederick L. Moffat

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Somatostatin receptor expression, which was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by in vivo imaging with 111In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.

Original languageEnglish (US)
Pages (from-to)243-245
Number of pages3
JournalJournal of Nuclear Medicine
Volume39
Issue number2
StatePublished - Feb 1 1998

    Fingerprint

Keywords

  • Hurthle cell cancer
  • Indium-111- pentetreotide
  • Somatostatin receptors
  • Thyroid cancer

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Gulec, S. A., Serafini, A. N., Sridhar, K. S., Peker, K. R., Gupta, A., Goodwin, W. J., Sfakianakis, G. N., & Moffat, F. L. (1998). Somatostatin receptor expression in Hurthle cell cancer of the thyroid. Journal of Nuclear Medicine, 39(2), 243-245.